Myx is predominately owned by institutions . Mum and dad investors are unlikely to have any impact on the SP . One needs to listen to the Feb results presentation to understand why the business is looking a lot better than 6 months ago . Myx has had a marked uptick in revenue and margin in Sep - dec 17 with further strength in Jan . Since then they have launched four new drugs to the market. With gorss operating margins increasing along with sales and cost savings from brining production in house it would not be surprising to see EPS around the 4c mark for the half. Apply an market PE of 14 to the annualised 8c and one gets a SP of 1.12 . This is arguably conservative as most pharma companies trade at a PE close to 18 -20.
Improtantly with the large capex behind us, cash flow generation and debt reduction is also likely to be solid , all these things will lift sentiment and intrinsic value and the SP
MYX Price at posting:
68.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)